Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 4,301–4,400 of 10,906
Homan, T., Mazzilli, S., Chieti, A., Musa, A., Roth, A., Fortunato, F., Bisceglia, L., Prato, R., Lopalco, P. L., & Martinelli, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-23235-4 · Cited by 16
COVID-19 primary series and booster vaccination and potential for immune imprintingPreprint
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.10.31.22281756 · Cited by 14
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity
Tobias, J., Steinberger, P., Wilkinson, J., Klais, G., Kundi, M., & Wiedermann, U. (2024) · Vaccines · doi:10.3390/vaccines12070795 · Cited by 17
Łysek-Gładysińska, M., Starz, M., Borowiec-Sęk, A., Sufin, I., Wieczorek, A., Chrapek, M., Zarębska‐Michaluk, D., Sufin, P., Głuszek, S., & Adamus-Białek, W. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s394760 · Cited by 17
Abou-Saleh, H., Halawa, B. Y. A., Younes, S. N., Younes, N., Al‐Sadeq, D. W., Shurrab, F. M., Liu, N., Qotba, H. A., Al-Dewik, N. I. E., Ismail, A., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac130 · Cited by 18
Alva, C., Vidaković, I., Lorber, B., Schachner-Nedherer, A.-L., Zettl, M., Khinast, J., Prassl, R., & Hsiao, W. (2022) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-022-09643-z · Cited by 14
Ethical reflections on Covid-19 vaccines
Raus, K., Mortier, E. P., & Eeckloo, K. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1925027 · Cited by 14
SARS-CoV-2 Vaccines and the Skin
Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2021.07.028 · Cited by 15
Gregersen, C. H., Mearraoui, R., Søgaard, P. P., Clergeaud, G., Petersson, K., Urquhart, A. J., & Simonsen, J. B. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114219 · Cited by 14
Collins, E., Ji, J., Kim, S.-G., Witten, J. J., Kim, S., Zhu, R., Park, P., Jung, M., Park, A., Manan, R. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68818-1 · Cited by 30
Pettini, E., Medaglini, D., & Ciabattini, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058748 · Cited by 15
Abdel‐Bakky, M. S., Amin, E., Ewees, M. G., Mahmoud, N. I., Mohammed, H. A., Altowayan, W. M., & Abdellatif, A. A. H. (2022) · Viruses · doi:10.3390/v14020228 · Cited by 17
Early Mortality After the First Dose of COVID-19 Vaccination: A Target Trial Emulation
McConeghy, K. W., Hur, K., Dahabreh, I. J., Jiang, R., Pandey, L., Gellad, W. F., Glassman, P. A., Good, C. B., Miller, D. R., Zullo, A. R., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad604 · Cited by 15
Alimohammadi, R., Porgoo, M., Eftekhary, M., Kiaie, S. H., Dezfouli, E. A., Dehghani, M., Nasrollahi, K., Malekshahabi, T., Heidari, M., Pouya, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00528-3 · Cited by 15
COVID Vaccination as a Strategy for Cardiovascular Disease Prevention
Fundora, M. P., Kamidani, S., & Oster, M. E. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01950-2 · Cited by 16
Violán, C., Carrasco-Ribelles, L., Collatuzzo, G., Ditano, G., Abedini, M., Janke, C., Reinkemeyer, C., Giang, L. T. T., Liviero, F., Scapellato, M. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11081340 · Cited by 14
Javanbakht, M., Khan, L., Mustanski, B. S., SHOPTAW, S. J., Baum, M. K., Mehta, S. H., Kirk, G. D., Lai, S., Moore, R. D., Milloy, M., et al. (2023) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2023.102300 · Cited by 14
Sharma, A., Oda, G., & Holodniy, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac325 · Cited by 18
Wang, Y., Wei, X., Liu, Y., Li, S., Pan, W., Dai, J., & Yang, Z. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1412478 · Cited by 22
Ye, X., Ye, W., Yu, J., Gao, Y., Ren, Z., Chen, L., Dong, A., Qian, Y., Zhan, C., Lin, Y., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1985354 · Cited by 15
Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 20
Simão, A. L., Palma, C. S., Izquierdo‐Sánchez, L., Putignano, A., Carvalho‐Gomes, Â., Posch, A., Zanaga, P., Gîrleanu, I., Henrique, M. M., Araújo, C., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100697 · Cited by 14
Chalkias, S., Schwartz, H., Nestorova, B., Feng, J., Chang, Y., Zhou, H., Dutko, F. J., Edwards, D. K., Montefiori, D. C., Pajón, R., et al. (2022) · medRxiv · doi:10.1101/2022.03.04.22271830 · Cited by 13
Self-citationCost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study
Du, Z., Wang, L., Bai, Y., Wang, X., Pandey, A., Fitzpatrick, M. C., Chinazzi, M., y Piontti, A. P., Hupert, N., Lachmann, M., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100182 · Cited by 16
Li, D., Debbas, P., Mujukian, A., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac174 · Cited by 14
Case of acquired haemophilia a in Southeast Asia following COVID-19 vaccine
Vuen, L. A., Su-Yin, E. A., Kori, A. N., & Shah, T. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-246922 · Cited by 14
Leong, D. P., Banerjee, A., & Yusuf, S. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.04.012 · Cited by 16
Kanji, J. N., Bailey, A., Fenton, J., Ling, S. H., Rivera, R., Plitt, S. S., Sligl, W., Taylor, S. C., Turnbull, L., Tipples, G. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.022 · Cited by 13
Lapić, I., Rogić, D., Šegulja, D., & Zaninović, L. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207572 · Cited by 13
Anti-COVID-19 Credentials of Chitosan Composites and Derivatives: Future Scope?
Gopal, J., Muthu, M., Pushparaj, S. S. C., & Sivanesan, I. (2023) · Antibiotics · doi:10.3390/antibiotics12040665 · Cited by 15
Giesen, N., Busch, E., Schalk, E., Beutel, G., Rüthrich, M. M., Hentrich, M., Hertenstein, B., Hirsch, H. H., Karthaus, M., Khodamoradi, Y., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.030 · Cited by 15
Thompson, K. M., Kalkowska, D. A., & Badizadegan, K. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1891889 · Cited by 14
Peanut oral immunotherapy: current trends in clinical trials
Reinwald, S., Rolland, J. M., O’Hehir, R. E., & van Zelm, M. C. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac004 · Cited by 18
Peterhoff, D., Einhauser, S., Beileke, S., Niller, H.-H., Günther, F., Schachtner, M., Asbach, B., Steininger, P. A., Tenbusch, M., Peter, A. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10020324 · Cited by 14
Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy
Wahab, S., Ghazwani, M., Hani, U., Hakami, A. R., Almehizia, A. A., Ahmad, W., Ahmad, M. Z., Alam, P., & Annadurai, S. (2023) · Molecules · doi:10.3390/molecules28031216 · Cited by 16
Kidney Transplant Recipient Attitudes Toward a SARS-CoV-2 Vaccine
Ou, M. T., Boyarsky, B. J., Zeiser, L. B., Chiang, T. P., Ruddy, J. A., Rasmussen, S. E. V. P., Martin, J., Russell, J. S. C., Durand, C. M., Avery, R. K., et al. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001171 · Cited by 16
Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients
Hirama, T., Akiba, M., Shundo, Y., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.04.019 · Cited by 14
Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVID‐19
Bollineni, S., Mahan, L. D., Duncan, P., Mohanka, M. R., LAWRENCE, A. C., JOERNS, J. O., Timofte, I., Torres, F., Hoz, R. M. L., Kershaw, C. D., et al. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13784 · Cited by 14
Divalent Metal Ions Boost Effect of Nucleic Acids Delivered by Cell-Penetrating Peptides
Maloverjan, M., Padari, K., Abroi, A., Rebane, A., & Pooga, M. (2022) · Cells · doi:10.3390/cells11040756 · Cited by 13
Xue, W., Li, T., Gu, Y., Li, S., & Xia, N. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2227699 · Cited by 21
Targeting Viral Surface Proteins through Structure-Based Design
Narkhede, Y. B., Gonzalez, K. J., & Strauch, E. (2021) · Viruses · doi:10.3390/v13071320 · Cited by 16
Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Levine, S., François, F., Iturrate, E., Wang, G., Dittmann, M., Lighter, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104141 · Cited by 15
Tan, D. H. S., Chan, A. K., Jüni, P., TOMLINSON, G. A., Daneman, N., Walmsley, S. L., Muller, M. P., Fowler, R. A., Murthy, S., Press, N., et al. (2021) · Trials · doi:10.1186/s13063-021-05134-7 · Cited by 15
Casado, J. L., Häemmerle, J., Vizcarra, P., Rodríguez-Domínguez, M., Velasco, T., Velasco, H., Centenera, E., Romero‐Hernández, B., Fernández-Escribano, M., & Vallejo, A. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1341 · Cited by 13
Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNAPreprint
Lewis, M. M., Beck, T. J., & Ghosh, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.09.565872 · Cited by 18
Kakavandi, S., Hajikhani, B., Azizi, P., Aziziyan, F., Nabi‐Afjadi, M., Farani, M. R., Zalpoor, H., Azarian, M., Saadi, M. I., Gharesi‐Fard, B., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01316-9 · Cited by 18
Tougeron, D., Hentzien, M., Seitz‐Polski, B., Bani‐Sadr, F., Bourhis, J., Ducreux, M. P., Gaujoux, S., Gorphe, P., Guiu, B., Hoang‐Xuan, K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.030 · Cited by 15
Budhadev, D., Hooper, J., Rocha, C., Nehlmeier, I., Kempf, A., Hoffmann, M., Krüger, N., Zhou, D.-J., Pöhlmann, S., & Guo, Y. (2023) · JACS Au · doi:10.1021/jacsau.3c00163 · Cited by 11
The SARS-CoV-2 antibody-dependent enhancement façade
Coish, J. M., MacNeil, L. A., & MacNeil, A. J. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2024.105464 · Cited by 13
Myocarditis following COVID-19 vaccination
Kaul, R., Sreenivasan, J., Goel, A., Malik, A. H., Bandyopadhyay, D., Jin, C., Sharma, M., Levine, A., Pan, S., Fuisz, A., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100872 · Cited by 14
mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics
Dalabehera, M., Ghosh, A., Mohanty, S., Chellappan, D. K., Chaudhari, S., Ale, Y., Poonia, N., Subudhi, R. N., Khanna, M., & Lim, H. G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102584 · Cited by 27
“…even current mRNA-LNPs formulations can trigger reactogenic effects in a dose-dependent manner, and repeated dosing may be limited by immune reactions against delivery components (for instance, anti-polyethylene glycol (PEG) antibodies can form, since many LNPs incorporate PEGylated lipids) [2].”
InfluentialMcIntosh, L., Rosen, M. P., Mittal, K., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102220 · Cited by 14
Tyner, H. L., Burgess, J. L., Grant, L., Gaglani, M., Kuntz, J. L., Naleway, A. L., Thornburg, N. J., Caban-Martinez, A. J., Yoon, S. K., Herring, M. K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1038 · Cited by 14
Cai, Y., Chen, Y., Xiao, L., Khor, S., Liu, T., Han, Y. K., Yuan, Y., Cai, L., Zeng, G., & Wang, X. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05023 · Cited by 19
Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting
Garces, K. N., Cocores, A. N., Goadsby, P. J., & Monteith, T. (2022) · Current Pain and Headache Reports · doi:10.1007/s11916-022-01094-y · Cited by 14
Keresztes, G., Baer, M., Alfenito, M. R., Verwoerd, T. C., Kovalchuk, A., Wiebe, M. G., Andersen, T. K., Saloheimo, M., Tchelet, R., Kensinger, R. D., et al. (2022) · Vaccines · doi:10.3390/vaccines10020148 · Cited by 15
Klebanoff, S. D., Rodda, L. B., Morishima, C., Wener, M. H., Yuzefpolskiy, Y., Bettelli, E., Buckner, J. H., Speake, C., Pepper, M., & Campbell, D. (2023) · JCI Insight · doi:10.1172/jci.insight.168663 · Cited by 14
Reimann, H., Kremer, A. N., Blumenberg, V., Schmidt, K. G., Aigner, M., Jacobs, B., Eisenhauer, N., Kämpf, A., Rösler, W., Kharboutli, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007806 · Cited by 18
McCollum, C. R., Courtney, C. M., O’Connor, N. J., Aunins, T. R., Jordan, T. X., Rogers, K. L., Brindley, S. M., Brown, J. M., Nagpal, P., & Chatterjee, A. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00669 · Cited by 12
Levi, N., Moravsky, G., Weitsman, T., Amsalem, I., Itach, S. B., Algur, N., Lapidus, I., Mitz, O., Glikson, M., Weil‐Weiner, Y., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2687 · Cited by 15
Nguyen, S., Bastien, E., Chrétien, B., Sassier, M., Defer, G. L., Nehme, A., Lelong‐Boulouard, V., Alexandre, J., Fédrizzi, S., & Morice, P. (2022) · Annals of Neurology · doi:10.1002/ana.26494 · Cited by 15
The global patent landscape of mRNA for diagnosis and therapy
Lyu, M., Chen, J., Peng, Y., Han, F., Gong, L., Guo, J., Tian, L., & Gao, Y. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01925-2 · Cited by 16
Li, L., Zheng, C., La, J., Do, N., Monach, P. A., Strymish, J. M., Fillmore, N. R., & Branch‐Elliman, W. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.026 · Cited by 15
Niebel, D., Wilhelmi, J., de Vos, L., et al. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.16210 · Cited by 14
Zabaleta, N., Bhatt, U., Hérate, C., Maisonnasse, P., Sanmiguel, J. C., Diop, C. T., Castore, S., Estelien, R., Li, D., Dereuddre‐Bosquet, N., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.007 · Cited by 17
Cantoni, D. M., Siracusano, G., Neto, M. M., Pastori, C., Fantoni, T., Lytras, S., Genova, C. D., Hughes, J., on behalf of the Ambulatorio Medico San Luca Villanuova Group, Lopalco, L., et al. (2022) · Vaccines · doi:10.3390/vaccines11010058 · Cited by 14
Gaweł, A., Mańdziuk, M. E., Żmudziński, M. A., Gosek, M., Krawczyk-Suszek, M., Pisarski, M., Adamski, A., & Cyganik, W. (2021) · Vaccines · doi:10.3390/vaccines9121487 · Cited by 21
Seban, R., Richard, C., Nascimento-Leite, C., Ghidaglia, J., Provost, C., Gonin, J., Tourneau, C. L., Romano, E., Deleval, N., & Champion, L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263082 · Cited by 14
Alcohol use disorder in the COVID‐19 era: Position paper of the Italian Society on Alcohol (SIA)
Testino, G., Vignoli, T., Patussi, V., Allosio, P., Amendola, M. F., Aricò, S., Baselice, A., Balbinot, P., Campanile, V., Fanucchi, T., et al. (2021) · Addiction Biology · doi:10.1111/adb.13090 · Cited by 14
Ocular motility disorders following coronavirus disease-19 vaccination
Park, K., Jeon, H., Choi, D. G., Jung, J. H., Shin, H.-J., Lee, B. J., Moon, Y., Lee, D. C., Lee, D. C., Cho, S. Y., et al. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05888-z · Cited by 15
Milito, C., Soccodato, V., Collalti, G., et al. (2021) · Vaccines · doi:10.3390/vaccines9060626 · Cited by 14
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.29.573647 · Cited by 13
Wnorowska, S., Targowska‐Duda, K. M., Kurzepa, J., et al. (2022) · Industrial Crops and Products · doi:10.1016/j.indcrop.2022.115338 · Cited by 14
Benin, A. L., Soe, M. M., Edwards, J. R., et al. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.08.004 · Cited by 14
Germany’s fourth COVID-19 wave was mainly driven by the unvaccinated
Maier, B. F., Wiedermann, M., Burdinski, A., Klamser, P., Jenny, M. A., Betsch, C., & Brockmann, D. (2022) · Communications Medicine · doi:10.1038/s43856-022-00176-7 · Cited by 19
The use of face masks during vaccine roll-out in New YorkCity and impact on epidemic control
MacIntyre, C. R., Costantino, V., & Chanmugam, A. S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.102 · Cited by 15
Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis
Ionita, C., Marcelli, D., Nita, C., Anton, C., Berca, S., Vacar, S., Schiller, O., Gheorghiu, C., & Barth, C. (2022) · Journal of Nephrology · doi:10.1007/s40620-021-01195-8 · Cited by 12
Abe, S., Takata, H., Shimizu, T., Kawaguchi, Y., Fukuda, S., Yamamoto, H., Ando, H., & Ishida, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113821 · Cited by 22
Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination
Horvat, J. V., Sevilimedu, V., Becker, A. S., Pérez-Johnston, R., Yeh, R., & Feigin, K. (2022) · European Radiology · doi:10.1007/s00330-022-08655-0 · Cited by 14
Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple modelPreprint
Gog, J. R., Hill, E. M., Danon, L., et al. (2021) · medRxiv · doi:10.1101/2021.03.14.21253544 · Cited by 14
COVID-19: The Pseudo-Environment and the Need for a Paradigm Change
Stein, R. A., Ometa, O., & Broker, T. R. (2021) · GERMS · doi:10.18683/germs.2021.1283 · Cited by 18
Coudeville, L., Jollivet, O., Mahé, C., Chaves, S. S., & Gomez, G. B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250797 · Cited by 16
Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
Shabu, A., & Nishtala, P. S. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2209177 · Cited by 16
Peter, J. K., Wegner, F., Gsponer, S., Helfenstein, F., Roloff, T. C., Tarnutzer, R., Grosheintz, K., Back, M., Schaubhut, C., Wagner, S., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10050857 · Cited by 13
Callaghan, C. J., Curtis, R. M. K., Mumford, L. L., Whitaker, H., Pettigrew, G. J., Gardiner, D. D., Marson, L., Thorburn, D., White, S. A., Parmar, J., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004535 · Cited by 15
Tani, N., Ikematsu, H., Goto, T., Gondo, K., Inoue, T., Yanagihara, Y., Kurata, Y., Oishi, R., Minami, J., Onozawa, K., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac493 · Cited by 15
Bachelet, T., Bourdenx, J.-P., Martinez, C., Mucha, S., Martin-Dupont, P., Perier, V., & Pommereau, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257646 · Cited by 15
Rheumatology and COVID-19 at 1 year: facing the unknowns
Calabrese, L. H., & Winthrop, K. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-219957 · Cited by 15
A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response
Kim, W., Song, E. S., Lee, S. H., Yang, S. H., Cho, J., & Kim, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-58315-0 · Cited by 17
Nakagawa, N., Maruyama, S., Kashihara, N., Narita, I., & Isaka, Y. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02231-y · Cited by 15
Lack of immune response after mRNA vaccination to SARS‐CoV‐2 in a solid organ transplant patient
Rusk, D. S., Strachan, C. C., & Hunter, B. R. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27044 · Cited by 13
Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19
Saleem, A., Akhtar, M. F., Haris, M., & Abdel‐Daim, M. M. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00850-7 · Cited by 15
Fiorino, S., Tateo, F., de Biase, D., Gallo, C. G., Orlandi, P. E., Corazza, I., Budriesi, R., Micucci, M., Visani, M., Loggi, E., et al. (2021) · Future Microbiology · doi:10.2217/fmb-2021-0064 · Cited by 16
Vandeputte, J., Damme, P. V., Neyts, J. H., Audonnet, J.-C., Baay, M. F. D., & Neels, P. (2021) · Biologicals · doi:10.1016/j.biologicals.2021.08.001 · Cited by 14
Circular RNA-based protein replacement therapy mitigates osteoarthritis in male mice
Suo, J., Li, L., Tan, W., Yin, X., Wang, J., Shao, R., Sun, S., Guo, S.-K., Feng, J., Gao, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63343-z · Cited by 18
Prasad, N. K., Englum, B. R., Mayorga‐Carlin, M., Turner, D. J., Sahoo, S., Sorkin, J. D., & Lal, B. K. (2022) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2022.03.038 · Cited by 14
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.